Skip to content
Innokeys
  • HOME
  • ABOUT US
  • PRODUCTS
  • THE TEAM
  • PARTNERS
  • PUBLICATIONS
  • NEWS
  • CONTACT US
Innokeys

Uncategorized

Uncategorized

Children with diffuse intrinsic pons glioma (DIPG) benefit from nimotuzumab

ByInnokeys March 7, 2019March 21, 2019

The results of an international clinical trial were published in March 2019. Forty-two children aged 3 to 20 years suffering from diffuse…

Read More Children with diffuse intrinsic pons glioma (DIPG) benefit from nimotuzumabContinue


Innokeys Pte Ltd is a Singapore based limited liability company that was set up to leverage the value of innovation in the field of healthcare, especially in biopharmaceuticals.

  • ABOUT US
  • THE TEAM
  • BUSINESS
  • CAREER OPPORTUNITY
  • CONTACT US
CONTACTS

205 Balestier Road #02-06
The Mezzo
Singapore (329682)

© Copyrights Reserved INNOKEYS 2025

INNOVATIVE KEYS
TO HEALTH AND WELLBEING

  • HOME
  • ABOUT US
  • PRODUCTS
  • THE TEAM
  • PARTNERS
  • PUBLICATIONS
  • NEWS
  • CONTACT US